Connection

Christina Johnson to Genetic Vectors

This is a "connection" page, showing publications Christina Johnson has written about Genetic Vectors.
Connection Strength

0.371
  1. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
    View in: PubMed
    Score: 0.122
  2. An orthotopic bladder cancer model for gene delivery studies. J Vis Exp. 2013 Dec 01; (82):50181.
    View in: PubMed
    Score: 0.051
  3. Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer. BMC Cancer. 2011 May 12; 11:168.
    View in: PubMed
    Score: 0.043
  4. Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. 2009 Sep-Oct; 6(5):1612-9.
    View in: PubMed
    Score: 0.038
  5. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 Jan; 12(1):12-8.
    View in: PubMed
    Score: 0.028
  6. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22.
    View in: PubMed
    Score: 0.025
  7. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
    View in: PubMed
    Score: 0.022
  8. The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
    View in: PubMed
    Score: 0.021
  9. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther. 2000 Oct; 2(4):348-58.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.